Electronic nose for breath analysis after curative Surgery to detect distant metastases or locoregional recurrence of colon cancer

•The ‘Medisch Specialistisch Bedrijf’(MSB) of Isala has invested in The eNose Company, Zutphen, The Netherlands. The researchers have received a grant from the Innovation & Science fund Isala. •The eNose Company invests by making the eNose devices, disposable mouthpieces and analysis of the breath tests available.0 sites1,184 target enrollmentTBD

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Not specified
Sponsor: •The ‘Medisch Specialistisch Bedrijf’(MSB) of Isala has invested in The eNose Company, Zutphen, The Netherlands. The researchers have received a grant from the Innovation & Science fund Isala. •The eNose Company invests by making the eNose devices, disposable mouthpieces and analysis of the breath tests available.
Enrollment: 1184
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Steenhuis, E.G.M., Schoenaker, I.J.H., de Groot, J.W.B., Fiebrich, H.B., de Graaf, J.C., Brohet, R.M., van Dijk, J.D., van Westreenen, H.L., Siersema, P.D., de Vos tot Nederveen Cappel, W.H. (2020). Feasibility of volatile organic compound in breath analysis in the follow-up of colorectal cancer: A pilot study. European Journal of Surgical Oncology, 46(11), 2068-2073

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Observational non invasive

Investigators

Sponsor

Eligibility Criteria

Inclusion Criteria

•1\. Follow\-up patients with an intentional curative treatment of CRC stage I to IV
•a CRC treated with curative intent by means of a colorectal resection
•curative treatment of synchronous metastases in combination with colorectal resection
•curatively treated metachronous metastases, after colorectal resection
•2\. Age \= 18 years.

Exclusion Criteria

•1\. Not proficient in Dutch
•2\. Reason to believe that the patient cannot perform a breath test
•3\. CRC not treated curatively
•4\. CRC pT1N0Mx / pT1NxMx (patients receiving endoscopic control only)
•5\. Local (surgical or endoscopic) resection
•6\. Active treatment of other malignancies within the past three months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Not Applicable

The electronic nose as a diagnostic tool in the discrimination of COPD and controls

NL-OMON23287Academic Medical Center Amsterdam, The Netherlands120

Recruiting

Not Applicable

Exhaled breath analysis using eNose technology to detect acute cellular rejection and chronic lung allograft rejection in patients after lung transplantatioung transplantation

NL-OMON24102one200

Completed

Not Applicable

An electronic nose in the screening for COPD in an at risk population of (ex-)smokers.COPD, smoking

NL-OMON20180Academic Medical CenterUniversity of AmsterdamDept. Pulmonology, F5-260Meibergdreef 91105 AZ AmsterdamThe NetherlandsUniversity Medical Center UtrechtUniversity of UtrechtDept. PulmonologyHeidelberglaan 1003584 CX UtrechtThe NetherlandsThe Nelson Study Group (Nederlands-Leuvens Longkanker Screeningsonderzoek).250

Completed

Not Applicable

Breath Analysis Using an Electronic Nose in Non Alcoholic Fatty Liver DiseaseNon-alcoholic Fatty Liver Disease

NCT02950610University of Edinburgh90

Recruiting

Not Applicable

An electronic nose in the intensive care investigation of acute lung injury and acute respiratory distress syndrome.ALI, ARDS, eNOSE, sepsis, mechanical ventilation.ALI, ARDS, eNOSE, sepsis, beademing.

NL-OMON27329Academic Medical Center (AMC), Departments of Pulmonology and Intensive Care.150